Strain Name:

FVB-Tg(C3-1-TAg)cJeg/J

Stock Number:

003381

Availability:

Repository-Cryopreserved

Use Restrictions Apply, see Terms of Use

Description

Strain Information

Type Mutant Strain; Transgenic;
Additional information on Genetically Engineered Mutant Mice.
Specieslaboratory mouse
GenerationN?+2
 
Donating Investigator Jeff Green,   NIH

Appearance
albino
Related Genotype: Tycc/Tyrc

Description
This transgenic strain is a model for the study of multistage oncogenesis in the prostate and mammary glands. Male transgenic mice develop prostatic hyperplasia in early life that progresses to adenoma or adenocarcinoma in about half of the animals which survive longer 7 months of age. Female animals generally develop mammary intraepithelial neoplasia with similarities to DCIS by 3 months of age with subsequent development of mammary adenocarcinoma by 6 months of age in 100% of the animals. About 10 - 15% of female mice develop lung metastases, although lung metastases from prostate cancer is extremely rare. Bone metastases have not been observed. The phenotype for this transgene has been most extensively studied in the FVB/N background.

Control Information

  Control
   Noncarrier
   001800 FVB/NJ
 
  Considerations for Choosing Controls

Related Strains

Strains carrying   Tg(C3-1-TAg)cJeg allele
003382   B10.D2-Tg(C3-1-TAg)cJeg/J
003380   B6.FVB-Tg(C3-1-TAg)cJeg/J
View Strains carrying   Tg(C3-1-TAg)cJeg     (2 strains)

View Strains carrying other alleles of TAg     (13 strains)

Phenotype

Phenotype Information

View Research Applications

Research Applications
This mouse can be used to support research in many areas including:

Cancer Research
Increased Tumor Incidence (Mammary Gland Tumors)
Increased Tumor Incidence (Prostate Tumors)

Reproductive Biology Research
Gonadal Tumors
Prostate Tumors (Tetop Tet System)

TAg related

Apoptosis Research
Extracellular Modulators

Genes & Alleles

Gene & Allele Information

Allele Symbol Tg(C3-1-TAg)cJeg
Allele Name transgene insertion C, Jeffrey E Green
Allele Type Transgenic (random, expressed)
Common Name(s) C3(1)-SV40 T antigen; C3(1)/SV40; C3(1)/SV40T; C3(1)/T antigen (Tag); C3(1)/T(AG); C3(1)/TAg; Large T;
Mutation Made By Jeff Green,   NIH
Strain of OriginFVB/N
Expressed Gene TAg, SV40 large T-antigen, SV40
Simian virus 40 T antigen (SV40Tag) is a multifunctional regulatory protein that stimulates gene transcription and forms complexes with cell cycle-regulatory proteins such as Trp53 and Rb1 that are implicated in human breast cancer.
Promoter C3(1), C3(1), rat
General Note Founders f, g, i, j, k, and l were also generated. Two transgenic lines (c and l) were produced. A review from 1998 stated that line C was the one continued for further study (J:46513).

Male transgenic mice Male mice survive up to 11 months of age, and develop prostatic hyperplastic changes in early life that progress to adenoma or adenocarcinoma in about half of the animals which survive longer 7 months of age. Female transgenic mice generally develop mammary intraepithelial neoplasia with similarities to DCIS by 3 months of age with subsequent development of mammary adenocarcinoma by 6 months of age in 100% of the animals. Homozygous mothers can bear offspring but pregnancy appears to accelerate tumor development and foster mothers are required forpups due to lactation difficulties. Evidence of pulmonary metastases has been seen in both male and female mice, although lung metastases from prostate cancer is extremely rare. About 10 - 15% of transgenic female mice develop lung metastases. No bone metastases have been observed.

Molecular Note This transgene contains the rat prostatic binding protein C3 promoter (Pbpc3) and the wild-type allele of the SV40 large tumor antigen (TAg) gene. Founder c carried 6 copies of the transgene. [MGI Ref ID J:52786]

Genotyping

Genotyping Information

Genotyping Protocols

TAg, SV, STD PCR, vers. 2

Helpful Links

Optimizing PCR Protocols

References

References

Selected Reference(s)

Maroulakou IG; Anver M; Garrett L; Green JE. 1994. Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. Proc Natl Acad Sci U S A 91(23):11236-40. [PubMed: 7972041]  [MGI Ref ID J:52786]

Additional References

Jorcyk CL; Liu ML; Shibata MA; Maroulakou IG; Komschlies KL; McPhaul MJ ; Resau JH ; Green JE. 1998. Development and characterization of a mouse prostate adenocarcinoma cell line: ductal formation determined by extracellular matrix. Prostate 34(1):10-22. [PubMed: 9428383]  [MGI Ref ID J:45372]

Maroulakou IG; Shibata MA; Jorcyk CL; Chen XX; Green JE. 1997. Reduced p53 dosage associated with mammary tumor metastases in C3(1)/TAG transgenic mice. Mol Carcinog 20(2):168-74. [PubMed: 9364206]  [MGI Ref ID J:72307]

Shibata MA; Maroulakou IG; Jorcyk CL; Gold LG; Ward JM; Green JE. 1996. p53-independent apoptosis during mammary tumor progression in C3(1)/SV40 large T antigen transgenic mice: suppression of apoptosis during the transition from preneoplasia to carcinoma. Cancer Res 56(13):2998-3003. [PubMed: 8674054]  [MGI Ref ID J:72136]

Shibata MA; Ward JM; Devor DE; Liu ML; Green JE. 1996. Progression of prostatic intraepithelial neoplasia to invasive carcinoma in C3(1)/SV40 large T antigen transgenic mice: histopathological and molecular biological alterations. Cancer Res 56(21):4894-903. [PubMed: 8895741]  [MGI Ref ID J:72324]

Tg(C3-1-TAg)cJeg related

Calvo A; Feldman AL; Libutti SK; Green JE. 2002. Adenovirus-mediated Endostatin Delivery Results in Inhibition of Mammary Gland Tumor Growth in C3(1)/SV40 T-Antigen Transgenic Mice. Cancer Res 62(14):3934-8. [PubMed: 12124322]  [MGI Ref ID J:77958]

Calvo A; Yokoyama Y; Smith LE; Ali I; Shih SC; Feldman AL; Libutti SK; Sundaram R; Green JE. 2002. Inhibition of the mammary carcinoma angiogenic switch in C3(1)/SV40 transgenic mice by a mutated form of human endostatin. Int J Cancer 101(3):224-34. [PubMed: 12209972]  [MGI Ref ID J:78871]

Cardiff RD; Anver MR; Gusterson BA; Hennighausen L; Jensen RA; Merino MJ; Rehm S; Russo J; Tavassoli FA; Wakefield LM; Ward JM; Green JE. 2000. The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting [see comments] Oncogene 19(8):968-88. [PubMed: 10713680]  [MGI Ref ID J:61035]

Cha TL; Qiu L; Chen CT; Wen Y; Hung MC. 2005. Emodin down-regulates androgen receptor and inhibits prostate cancer cell growth. Cancer Res 65(6):2287-95. [PubMed: 15781642]  [MGI Ref ID J:97163]

Diwadkar-Navsariwala V; Prins GS; Swanson SM; Birch LA; Ray VH; Hedayat S; Lantvit DL; Diamond AM. 2006. Selenoprotein deficiency accelerates prostate carcinogenesis in a transgenic model. Proc Natl Acad Sci U S A 103(21):8179-84. [PubMed: 16690748]  [MGI Ref ID J:110207]

Green JE; Shibata MA; Shibata E; Moon RC; Anver MR; Kelloff G; Lubet R. 2001. 2-Difluoromethylornithine and Dehydroepiandrosterone Inhibit Mammary Tumor Progression but not Mammary or Prostate Tumor Initiation in C3(1)/SV40 T/t-antigen Transgenic Mice. Cancer Res 61(20):7449-55. [PubMed: 11606379]  [MGI Ref ID J:72279]

Green JE; Shibata MA; Yoshidome K; Liu ML; Jorcyk C; Anver MR; Wigginton J; Wiltrout R; Shibata E; Kaczmarczyk S; Wang W; Liu ZY; Calvo A; Couldrey C. 2000. The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma. Oncogene 19(8):1020-7. [PubMed: 10713685]  [MGI Ref ID J:61011]

Gupta V; Carey JL; Kawakubo H; Muzikansky A; Green JE; Donahoe PK; MacLaughlin DT; Maheswaran S. 2005. Mullerian inhibiting substance suppresses tumor growth in the C3(1)T antigen transgenic mouse mammary carcinoma model. Proc Natl Acad Sci U S A 102(9):3219-24. [PubMed: 15728372]  [MGI Ref ID J:97014]

Huh JI; Calvo A; Charles R; Green JE. 2006. Distinct tumor stage-specific inhibitory effects of 2-methoxyestradiol in a breast cancer mouse model associated with Id-1 expression. Cancer Res 66(7):3495-503. [PubMed: 16585173]  [MGI Ref ID J:108216]

Huh JI; Calvo A; Stafford J; Cheung M; Kumar R; Philp D; Kleinman HK; Green JE. 2005. Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms. Oncogene 24(5):790-800. [PubMed: 15592523]  [MGI Ref ID J:96009]

Jorcyk CL; Liu ML; Shibata MA; Maroulakou IG; Komschlies KL; McPhaul MJ ; Resau JH ; Green JE. 1998. Development and characterization of a mouse prostate adenocarcinoma cell line: ductal formation determined by extracellular matrix. Prostate 34(1):10-22. [PubMed: 9428383]  [MGI Ref ID J:45372]

Kavanaugh C; Green JE. 2003. The use of genetically altered mice for breast cancer prevention studies. J Nutr 133(7 Suppl):2404S-2409S. [PubMed: 12840216]  [MGI Ref ID J:85028]

Kouros-Mehr H; Bechis SK; Slorach EM; Littlepage LE; Egeblad M; Ewald AJ; Pai SY; Ho IC; Werb Z. 2008. GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. Cancer Cell 13(2):141-52. [PubMed: 18242514]  [MGI Ref ID J:131913]

Liu ML; Shibata MA; Von Lintig FC; Wang W; Cassenaer S; Boss GR; Green JE. 2001. Haploid loss of Ki-ras delays mammary tumor progression in C3 (1)/SV40 Tag transgenic mice. Oncogene 20(16):2044-9. [PubMed: 11360188]  [MGI Ref ID J:69250]

Liu ML; Von Lintig FC; Liyanage M; Shibata MA; Jorcyk CL; Ried T; Boss GR; Green JE. 1998. Amplification of Ki-ras and elevation of MAP kinase activity during mammary tumor progression in C3(1)/SV40 Tag transgenic mice. Oncogene 17(18):2403-11. [PubMed: 9811472]  [MGI Ref ID J:50935]

Liu R; Varghese S; Rabkin SD. 2005. Oncolytic herpes simplex virus vector therapy of breast cancer in C3(1)/SV40 T-antigen transgenic mice. Cancer Res 65(4):1532-40. [PubMed: 15735042]  [MGI Ref ID J:97030]

Maroulakou IG; Shibata MA; Anver M; Jorcyk CL; Liu Ml; Roche N; Roberts AB; Tsarfaty I; Reseau J; Ward J; Green JE. 1999. Heterotopic endochondrial ossification with mixed tumor formation in C3(1)/Tag transgenic mice is associated with elevated TGF-beta1 and BMP-2 expression. Oncogene 18(39):5435-47. [PubMed: 10498897]  [MGI Ref ID J:57996]

Maroulakou IG; Shibata MA; Jorcyk CL; Chen XX; Green JE. 1997. Reduced p53 dosage associated with mammary tumor metastases in C3(1)/TAG transgenic mice. Mol Carcinog 20(2):168-74. [PubMed: 9364206]  [MGI Ref ID J:72307]

Moody TW; Dudek J; Zakowicz H; Walters J; Jensen RT; Petricoin E; Couldrey C; Green JE. 2004. VIP receptor antagonists inhibit mammary carcinogenesis in C3(1)SV40T antigen mice. Life Sci 74(11):1345-57. [PubMed: 14706566]  [MGI Ref ID J:88119]

Nunez NP; Oh WJ; Rozenberg J; Perella C; Anver M; Barrett JC; Perkins SN; Berrigan D; Moitra J; Varticovski L; Hursting SD; Vinson C. 2006. Accelerated tumor formation in a fatless mouse with type 2 diabetes and inflammation. Cancer Res 66(10):5469-76. [PubMed: 16707476]  [MGI Ref ID J:109048]

Oakes SR; Robertson FG; Kench JG; Gardiner-Garden M; Wand MP; Green JE; Ormandy CJ. 2007. Loss of mammary epithelial prolactin receptor delays tumor formation by reducing cell proliferation in low-grade preinvasive lesions. Oncogene 26(4):543-53. [PubMed: 16862169]  [MGI Ref ID J:117839]

Shen Q; Brown PH. 2005. Transgenic mouse models for the prevention of breast cancer. Mutat Res 576(1-2):93-110. [PubMed: 15888345]  [MGI Ref ID J:100623]

Shibata MA; Jorcyk CL; Devor DE; Yoshidome K; Rulong S; Resau J; Roche N; Roberts AB; Ward JM; Green JE. 1998. Altered expression of transforming growth factor betas during urethral and bulbourethral gland tumor progression in transgenic mice carrying the androgen-responsive C3(1) 5' flanking region fused to SV40 large T antigen. Carcinogenesis 19(1):195-205. [PubMed: 9472712]  [MGI Ref ID J:45643]

Shibata MA; Jorcyk CL; Liu ML; Yoshidome K; Gold LG; Green JE. 1998. The C3(1)/SV40 T antigen transgenic mouse model of prostate and mammary cancer. Toxicol Pathol 26(1):177-82. [PubMed: 9502400]  [MGI Ref ID J:46513]

Shibata MA; Kavanaugh C; Shibata E; Abe H; Nguyen P; Otsuki Y; Trepel JB; Green JE. 2003. Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse models. Carcinogenesis 24(3):453-9. [PubMed: 12663504]  [MGI Ref ID J:82837]

Shibata MA; Liu ML; Knudson MC; Shibata E; Yoshidome K; Bandey T ; Korsmeyer SJ ; Green JE. 1999. Haploid loss of bax leads to accelerated mammary tumor development in C3(1)/SV40-TAg transgenic mice: reduction in protective apoptotic response at the preneoplastic stage. EMBO J 18(10):2692-701. [PubMed: 10329616]  [MGI Ref ID J:55778]

Shibata MA; Maroulakou IG; Jorcyk CL; Gold LG; Ward JM; Green JE. 1996. p53-independent apoptosis during mammary tumor progression in C3(1)/SV40 large T antigen transgenic mice: suppression of apoptosis during the transition from preneoplasia to carcinoma. Cancer Res 56(13):2998-3003. [PubMed: 8674054]  [MGI Ref ID J:72136]

Shibata MA; Ward JM; Devor DE; Liu ML; Green JE. 1996. Progression of prostatic intraepithelial neoplasia to invasive carcinoma in C3(1)/SV40 large T antigen transgenic mice: histopathological and molecular biological alterations. Cancer Res 56(21):4894-903. [PubMed: 8895741]  [MGI Ref ID J:72324]

Shibata MA; Yoshidome K; Shibata E; Jorcyk CL; Green JE. 2001. Suppression of mammary carcinoma growth in vitro and in vivo by inducible expression of the Cdk inhibitor p21. Cancer Gene Ther 8(1):23-35. [PubMed: 11219490]  [MGI Ref ID J:67442]

Verschoyle RD; Edwards R; Nolan B; Greaves P. 2004. Articular Chondromatosis and Chrondroid Metaplasia in Transgenic TAg Mice. Toxicol Pathol 32(1):22-5. [PubMed: 14713544]  [MGI Ref ID J:88112]

Wang Z; Prins GS; Coschigano KT; Kopchick JJ; Green JE; Ray VH; Hedayat S; Christov KT; Unterman TG; Swanson SM. 2005. Disruption of growth hormone signaling retards early stages of prostate carcinogenesis in the C3(1)/T antigen mouse. Endocrinology 146(12):5188-96. [PubMed: 16141391]  [MGI Ref ID J:104208]

Wigginton JM; Park JW; Gruys ME; Young HA; Jorcyk CL; Back TC; Brunda MJ; Strieter RM; Ward J; Green JE; Wiltrout RH. 2001. Complete regression of established spontaneous mammary carcinoma and the therapeutic prevention of genetically programmed neoplastic transition by IL-12/pulse IL-2: induction of local T cell infiltration, Fas/Fas ligand gene expression, and mammary epithelial apoptosis. J Immunol 166(2):1156-68. [PubMed: 11145697]  [MGI Ref ID J:66851]

Wild R; Yokoyama Y; Dings RP; Ramakrishnan S. 2004. VEGF-DT385 Toxin Conjugate Inhibits Mammary Adenocarcinoma Development in a Transgenic Mouse Model of Spontaneous Tumorigenesis. Breast Cancer Res Treat 85(2):161-71. [PubMed: 15111774]  [MGI Ref ID J:90175]

Wu K; Kim HT; Rodriquez JL; Hilsenbeck SG; Mohsin SK; Xu XC; Lamph WW; Kuhn JG; Green JE; Brown PH. 2002. Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069. Cancer Epidemiol Biomarkers Prev 11(5):467-74. [PubMed: 12010861]  [MGI Ref ID J:77199]

Wu K; Kim HT; Rodriquez JL; Munoz-Medellin D; Mohsin SK; Hilsenbeck SG; Lamph WW; Gottardis MM; Shirley MA; Kuhn JG; Green JE; Brown PH. 2000. 9-cis-Retinoic acid suppresses mammary tumorigenesis in C3(1)-simian virus 40 T antigen-transgenic mice Clin Cancer Res 6(9):3696-704. [PubMed: 10999763]  [MGI Ref ID J:64491]

Wu Y; Cui K; Miyoshi K; Hennighausen L; Green JE; Setser J; LeRoith D; Yakar S. 2003. Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors. Cancer Res 63(15):4384-8. [PubMed: 12907608]  [MGI Ref ID J:84849]

Yoshidome K; Shibata MA; Couldrey C; Korach KS; Green JE. 2000. Estrogen promotes mammary tumor development in C3(1)/SV40 large T-antigen transgenic mice: paradoxical loss of estrogen receptoralpha expression during tumor progression. Cancer Res 60(24):6901-10. [PubMed: 11156389]  [MGI Ref ID J:66915]

Zhang X; Mehta RG; Lantvit DD; Coschigano KT; Kopchick JJ; Green JE; Hedayat S; Christov KT; Ray VH; Unterman TG; Swanson SM. 2007. Inhibition of estrogen-independent mammary carcinogenesis by disruption of growth hormone signaling. Carcinogenesis 28(1):143-50. [PubMed: 16916863]  [MGI Ref ID J:116587]

Health & husbandry

Health & Colony Maintenance Information

Colony Maintenance

Diet Information LabDiet® 5K52/5K67

Purchasing information

Pricing, Supply Level & Notes, Controls, General Terms & Conditions

Pricing

Pricing for USA, Canada and Mexico shipping destinations View International pricing
Weeks of AgePrice*Gender
Cryorecovery Fee $1900.00
*Price(s) in US dollars ($)

Additional Supply Details

Pricing for International shipping destinations View USA Canada and Mexico pricing
Weeks of AgePrice*Gender
Cryorecovery Fee $2470.00
*Price(s) in US dollars ($)

Additional Supply Details

Supply Details

Standard SupplyRepository-Cryopreserved. Must Be Recovered. Please refer to pricing and supply notes for further information.
Supply Notes
  • Cryorecovery - Standard.
    The recovery process begins when a signed agreement form is returned to the Customer Service Department after order placement. Although results vary by strain, at least two males and two females (two pairs) will be provided, typically within 15 weeks of our receipt of the signed agreement form. If the first recovery attempt is unsuccessful or only one pair is recovered, a second recovery will be done, extending the delivery time to approximately 25 weeks. At least one member of each pair will be of known genotype and will carry the mutation if it is a mutant strain. Please note that pairs may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation of the strain. Mating schemes are sometimes modified for successful cryopreservation. Price represents a repository maintenance fee, which includes the cost of recovery of the strain from the cryopreservation resource and the periodic replacement of the frozen embryos used for recovery.

    Cryorecovery to establish a Dedicated Supply for greater quantities of mice.
    One to two pairs will be recovered to establish a Dedicated Supply of mice. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 or 1-207-288-5845.

  • This strain is included in the Induced Mutant Resource Colony collection.
  • Genomic DNA is available for this strain from the Mouse DNA Resource.

Control Information

  Control
   Noncarrier
   001800 FVB/NJ
 
  Considerations for Choosing Controls
  USA, Canada and Mexico - Control Pricing Information for Genetically Engineered Mutant Strains.
  International - Control Pricing Information for Genetically Engineered Mutant Strains.

General Terms and Conditions


See Terms of Use


The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.
Ordering and Purchasing Information

      Purchasing Information
      JAX® Mice Orders
      Surgical Services

Contact Information
Orders & Technical Support
Tel: 800.422.6423 or 207.288.5845
Fax: 207.288.6150
Technical Support Email Form

Terms of Use

Terms of Use


General Terms and Conditions


OncoMouse® requires a license from DuPont, see Licenses for Strains with OncoMouse® Technology.

Contact information

General inquiries

Contracts Administration

phone:207-288-6470
fax:207-288-6655

JAX® Mice & Services Conditions of Use

“Each recipient institution, including its employees and other researchers under its control (RECIPIENT), of mice or services using mice from The Jackson Laboratory (TJL) agrees that such mice, descendants of those mice derived by inbreeding or crossbreeding, including unmodified derivatives of those mice or their descendants (“MICE”) shall not be: (i) used for any purpose other than the internal research of the RECIPIENT, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services with respect to MICE. Acceptance of MICE from TJL shall be deemed agreement by RECIPIENT to these conditions, and departure from these conditions requires The Jackson Laboratory’s prior written authorization.”

No Warranty

MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. THE LABORATORY EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of MICE, products or services, The Jackson Laboratory will, at its option, provide credit or replacement for the MICE or product received or the services provided.

No Liability

In no event shall The Jackson Laboratory, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, products or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of The Jackson Laboratory, its agents or employees. In purchasing or receiving MICE, products or services from The Jackson Laboratory, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges The Jackson Laboratory from all such causes of action or damages, and further agrees to defend and indemnify The Jackson Laboratory from any costs or damages arising out of any third party claims.

MICE and biological materials are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to The Jackson Laboratory’s MICE, products and services. In addition, special terms and conditions of sale of certain MICE, products and services may be set forth separately in The Jackson Laboratory web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, products and services by The Jackson Laboratory, and by its licensees and distributors.

Acceptance of delivery of MICE, products or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on The Jackson Laboratory, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, products services by The Jackson Laboratory.


(3.2)